Genetic association between polymorphisms in the ADAMTS14 gene and multiple sclerosis

Robert Goertsches1, Manuel Comabella, Arcadi Navarro

  • 1Unitat de Neuroimmunologia Clínica, Hospital Universitari Vall d'Hebron (HUVH), Escuela de Enfermeria 2(a) planta, Psg Vall d'Hebron 119-129, 08035 Barcelona, Spain.

Insights

The ADAMTS14 gene may play a role in multiple sclerosis (MS) susceptibility. Specific genetic variations in ADAMTS14 were associated with relapsing-remitting MS and primary-progressive MS in a case-control study.

Area of Science:

  • Genetics
  • Neuroimmunology
  • Molecular Biology

Background:

  • ADAMTS14 is a metalloproteinase involved in extracellular matrix processing.
  • Multiple sclerosis (MS) is a complex neuroinflammatory disease with genetic components.
  • Investigating novel candidate genes is crucial for understanding MS predisposition.

Purpose of the Study:

  • To comprehensively investigate the ADAMTS14 gene as a candidate for multiple sclerosis (MS) susceptibility.
  • To analyze the association between ADAMTS14 single nucleotide polymorphisms (SNPs) and MS risk.
  • To explore potential links between ADAMTS14 variants and different clinical forms of MS.

Main Methods:

  • A case-control study design was employed.
  • Eight single nucleotide polymorphisms (SNPs) in the ADAMTS14 gene were analyzed.
  • Allele, genotype, and haplotype frequencies were compared between 287 MS patients and 285 controls.

Main Results:

  • Overall, SNPs 3 and 6 in ADAMTS14 showed association with MS.
  • Specific variants at SNP6 were linked to an increased risk of relapsing-remitting MS (RRMS).
  • Primary-progressive MS (PPMS) showed associations with variants at SNP2 and SNP3, and a specific haplotype (AGGGC).

Conclusions:

  • The ADAMTS14 gene is a potential susceptibility factor for multiple sclerosis.
  • Genetic variations in ADAMTS14 may influence the risk and potentially the clinical course of MS.
  • Further research is warranted to elucidate the functional role of ADAMTS14 in MS pathogenesis.

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...